康諾亞(02162.HK)TSLP靶點藥物I期臨牀研究獲積極主要研究結果
康諾亞(02162.HK)公佈,自主研發的1類新藥CM326注射液在健康人中開展的I期臨牀研究,已完成揭盲和統計分析,獲得積極的主要研究結果。
CM326是由康諾亞研發、具有全新作用機制和全球自主知識產權的1類創新藥,靶向胸腺基質淋巴細胞生成素(TSLP),爲國內首個進入臨牀研究階段的該靶點藥物。TSLP是炎症級聯反應的啓動因子之一,抑制TSLP可以從炎症發生的早期進行幹預,阻止免疫細胞釋放促炎細胞因子。TSLP與特應性皮炎、哮喘、慢性鼻竇炎等過敏性疾病的發生密切相關,是目前唯一被證明對低Th2型哮喘有效的靶點。臨牀前研究表明,CM326安全性良好、藥效優異,不同體外藥效學研究均證實本產品生物學活性明顯強於國外同靶點藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.